Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that David Nikodem, Ph.D., has joined its Board of Directors. Dr. Nikodem is a senior representative of the global healthcare-focused investment firm Ally Bridge Group.
“David brings a wealth of public markets experience, and I am delighted to welcome him to our Board. Adding an influential global healthcare investment group, like Ally Bridge, to our investor base represents an important milestone for Alzheon and will help us rapidly progress ALZ-801, one of only a handful of innovative drug candidates with the potential to reach Alzheimer’s disease patients in the next few years,” said Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer of Alzheon.
Help employers find you! Check out all the jobs and post your resume.
